OREANDA-NEWS. Boston Scientific Corporation (NYSE: BSX) announced today that Professor Ian Meredith AM will join the company as executive vice president and global chief medical officer in January 2017. In his new position, Professor Meredith will lead clinical and medical affairs across Boston Scientific and will provide global leadership of the company's clinical trial strategy.

Professor Meredith will succeed Executive Vice President and Global Chief Medical Officer Keith Dawkins, M.D., who has announced his intention to retire from the company in January 2017.  

"Ian is one of the world's leading cardiac device clinical investigators and he has been an advisor to Boston Scientific for many years," said Mike Mahoney, chairman and chief executive officer, Boston Scientific. "His strong relationships within the global research and clinical community and his track record applying novel technologies to advance science and care for patients make him ideally suited to drive innovation and succeed Keith in this role. We are delighted that he will be joining our team."

"We thank Keith for his many contributions to Boston Scientific during the last nine years. His deep clinical, medical and strategic expertise and advocacy for the patient will have lasting influence within our company," said Mahoney.

Professor Meredith currently serves as professor of Medicine and Cardiology for Monash University, Director of MonashHeart and Monash Health and as executive director of the Monash Cardiovascular Research Centre in Melbourne, Australia. He brings to Boston Scientific more than 25 years of experience as a clinical and interventional cardiologist. He has performed more than 10,000 invasive cardiac and coronary procedures, published more than 300 manuscripts and has been chief or principal investigator on 30 major international multi-center trials, including first-in-man trials of new drug-eluting stents. Professor Meredith's work has focused on the development and clinical evaluation of devices for the treatment of coronary artery and structural heart disease, and he has been at the forefront of emerging percutaneous cardiac valve therapies. He was also the global principal investigator for the Boston Scientific Lotus™ Valve REPRISE research program.

"Boston Scientific has demonstrated a commitment to delivering meaningful innovation and I look forward to joining the team to further develop the technology pipeline and deliver solutions for patients worldwide," said Professor Meredith.

Professor Meredith received undergraduate and doctorate degrees from Monash University in Melbourne, Australia. He trained in Melbourne and completed his Ph.D. at the Baker Institute before spending three years at the Brigham & Women's Hospital and Harvard Medical School in Boston.

About Boston Scientific
Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world.  As a global medical technology leader for more than 35 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare.